| Authors: |
Bakker C; Centre for Human Drug Research (CDHR), Zernikedreef 8, 2333 CL, Leiden, The Netherlands., Tasker T; Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK., Liptrot J; Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK., Hart EP; Centre for Human Drug Research (CDHR), Zernikedreef 8, 2333 CL, Leiden, The Netherlands., Klaassen ES; Centre for Human Drug Research (CDHR), Zernikedreef 8, 2333 CL, Leiden, The Netherlands., Doll RJ; Centre for Human Drug Research (CDHR), Zernikedreef 8, 2333 CL, Leiden, The Netherlands., Brown GA; OMass Therapeutics Ltd, Oxford, UK., Brown A; Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK., Congreve M; Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK., Weir M; Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK., Marshall FH; Merck Sharp & Dohme Limited, London, UK., Cross DM; Cross Pharma Consulting Limited, Cambridge, UK., Groeneveld GJ; Centre for Human Drug Research (CDHR), Zernikedreef 8, 2333 CL, Leiden, The Netherlands. ggroeneveld@chdr.nl.; Leiden University Medical Centre, Leiden, The Netherlands. ggroeneveld@chdr.nl., Nathan PJ; Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK.; Department of Psychiatry, University of Cambridge, Cambridge, UK.; School of Psychological Sciences, Monash University, Melbourne, Australia. |
